dkd treatment update: sglt2 inhibitors and finerenone | ian de boer & amrit lamba
Published 3 years ago • 5.8K plays • Length 18:00Download video MP4
Download video MP3
Similar videos
-
6:11
dapa-ckd: does confirmed renoprotection make the case for first-line sglt2 inhibition? | luigi gnudi
-
7:22
figaro: where will finerenone fit into diabetic kidney disease treatment | david wheeler
-
11:01
why sglt2 inhibitors cause euglycemic dka
-
7:21
sglt2 inhibitors - how it helps in reducing blood glucose?
-
8:14
dapa-ckd: renal benefits of sglt2 inhibition in people with and without diabetes | hiddo heerspink
-
16:10
how sglt-2 inhibitors work: with pros and cons - jardiance, farxiga, invokana -type 2 diabetes#15
-
10:38
use kerendia to stop diabetic kidney disease!
-
24:19
why do sglt2 inhibitors lead to erythrocytosis?
-
1:06:11
iscp 2021 dapagliflozin et al. the growing therapeutic spectrum of sglt2i
-
4:19
sglt2 inhibitors (gliflozins)
-
5:13
sglt2 inhibitor trials - summary
-
8:27
emperor-preserved: diabetes medication becomes first effective hfpef therapy | stefan anker
-
1:00:20
sglt2 inhibitor interdisciplinary forum
-
9:53
management of type 1 diabetes: ada/easd consensus report | anne peters
-
34:04
george bakris, md | use of finerenone in patients with diabetes who have kidney disease
-
56:59
sglt 2 therapy: the gift that keeps giving
-
59:47
nov 2022 - sglt2 inhibition by dapagliflozin mitigates peritoneal fibrosis & ultrafiltration failure
-
2:25:41
sglt2 inhibitor (dapagliflozin) trials in diabetes, kidney disease and heart failure.
-
9:55
how sglt2 inhibitors protect the kidney in patients with diabetes mellitus?
-
2:59
assimilating the evidence in t2dm: cardiovascular and renal outcomes with sglt2 inhibitors
-
1:04:03
sglt2i, glip-1a and mra in cardiorenal protection | monique cho
-
7:16
sglt2 inhibitors as standard of care throughout cardiology